CPC A61K 35/742 (2013.01) [A01K 67/0275 (2013.01); A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 35/74 (2013.01); A61K 39/0008 (2013.01); A61K 39/08 (2013.01); A61K 39/39 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C12Q 1/689 (2013.01); G01N 33/505 (2013.01); A01K 2267/0325 (2013.01); A61K 35/00 (2013.01); A61K 2039/52 (2013.01); A61K 2039/542 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/57 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/33 (2013.01); G01N 2500/10 (2013.01)] | 9 Claims |
1. A pharmaceutical composition comprising a spore-forming fraction of human fecal matter;
wherein the pharmaceutical composition is formulated for oral administration;
wherein the spore-forming fraction of human fecal matter in the pharmaceutical composition has been obtained by enriching human fecal matter for a population of spore-forming bacteria therein and comprises two or more bacterial strains; and
wherein the spore-forming fraction of human fecal matter in the pharmaceutical composition induces proliferation and/or accumulation of regulatory T cells and wherein the pharmaceutical composition is in the form of a capsule.
|